INTRODUCTION AND OBJECTIVES: Current guidelines recommend !3 cycles of cisplatin-based neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (MIBC). The impact of suboptimal NAC dosing on survival outcomes after radical cystectomy (RC) has been poorly investigated. We aimed to assess the prevalence of and factors association with receiving suboptimal NAC and its impact on survival outcomes in MIBC patients treated with RC.
INTRODUCTION AND OBJECTIVES: Current guidelines recommend !3 cycles of cisplatin-based neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (MIBC). The impact of suboptimal NAC dosing on survival outcomes after radical cystectomy (RC) has been poorly investigated. We aimed to assess the prevalence of and factors association with receiving suboptimal NAC and its impact on survival outcomes in MIBC patients treated with RC.
METHODS: We reviewed 1,441 patients treated with NAC and/ or RC for cT2-cT4N0M0 BC. Patients were segregated into three groups: suboptimal NAC (<3 cycles of cisplatin-based NAC or noncisplatin-based regimen); optimal NAC; and no NAC. Clinical characteristics were compared among groups. Comorbidities were scored with the Charlson Comorbidity Index (CCI). Complete pathological response to NAC was defined as ypT0N0. Logistic regression analyses tested the association between clinical variables and the odds of receiving suboptimal NAC. To adjust for potential baseline confounders, propensity-score matching was performed. Pathologic outcomes were compared between groups and Cox regression analyses tested risk factors associated with recurrence, overall and cancer specific survival.
RESULTS: Before matching, 251 (17.4%) and 86 (6.0%) patients received optimal NAC and suboptimal NAC while 1104 (76.6%) underwent upfront RC. Low eGFR values (p<0.001), CCI!1 (p[0.02) and ECOG!1 (p[0.02) were associated with the administration of a suboptimal NAC. After matching, 158 (38.3%), 85 (20.6%) and 169 (41.1%) patients were in the optimal NAC, suboptimal NAC and no NAC group. Positive nodal status was more frequently found in the suboptimal (37.6%) and in the no NAC group (28.9%) than in the optimal NAC group (22.7%) (p[0.038). The optimal NAC group achieved higher rates of complete pathological response as compared to the suboptimal group (26.1% vs. 15.3%; p[0.03) . Five-year RFS (p[0.013) and CSM-free rates (p<0.001) were higher for the optimal than suboptimal and no NAC group. Multivariable analysis showed that, suboptimal NAC (HR 1.74; p[0.015) As a result, they experience high complications rates, frequent readmissions, poor quality of life (QOL) and require substantial medical resources. Strategies to improve outcomes and expand patient eligibility for cystectomy are lacking. Herein, we prospectively evaluate the feasibility, safety and impact of a prehabilitation program for patients undergoing cystectomy for bladder cancer.
METHODS: This phase I/II study accrued patients !60 years old from 03/2013-10/2017 with biopsy-proven bladder cancer, Karnofsky performance score !70 and a sedentary baseline lifestyle. All subjects were prescribed a 4 week (3 sessions per week) supervised, escalating pre-operative strength and cardiovascular exercise training program. Primary outcomes were feasibility and safety; secondary outcomes included changes in functional fitness, patient-reported QOL, peri-operative complications and readmissions.
RESULTS: Fifty-four patients enrolled in the program, completing 85.7% (SD 20.7%) of the prescribed exercise sessions. There were no adverse events. Functional fitness and patient-reported QOL improved post-intervention, with sustained improvements in general and mental health 90-days post-surgery (Table 1, Figure 1) . The 90-day complication rate was 43%; the readmission rate was 20% which is not statistically decreased when compared to our historic cohort (29%, p[0.14).
CONCLUSIONS: Prehabilitation prior to cystectomy is feasible, safe, and results in marked improvements in patient strength and sustained improvements in patient-reported QOL from baseline. There was an encouraging trend toward decreased readmissions but this did not reach statistical significance. Efforts to further evaluate the impact of prehabilitation in this population in an expanded and randomized fashion are warranted.
